



2025 Development Grants for Funding Commencing in 2026

The objectives of the Development Grant scheme are to expedite the translation of health and medical research outcomes through to commercialisation within a foreseeable timeframe by supporting proof-of-concept research with a feasible commercialisation pathway and a high likelihood of producing protected IP.

The intended outcomes of the Development Grant scheme are increased rates of translation of health and medical research into commercial outcomes, resulting in improved health and medical knowledge.

The 2025 Development Grants funding round seeking applications for funding commencing in 2026 opened on 16 April 2025. Applications closed on 11 June 2025 with 181 applications received.

The applications listed in the table below have been approved for funding by the Minister for Health and Ageing, the Hon Mark Butler MP.

App ID	Chief Investigator Names	Application Title	Administering Institution	Budget
2049624	CIA – Prof Christopher McDevitt CIB – Dr David Stamler CIC – Prof Toni Velkov CID – Assoc Prof Norelle Sherry	Translational development of an antibiotic potentiator for bacterial pneumonia	University of Melbourne	\$1,213,478.00
2049641	CIA – Prof Gregory Monteith CIB – Dr Brian Dymock CIC – Dr Kimberley Beaumont CID – Dr Rebecca Pouwer CIE – Dr Melanie Robitaille	Advancing a first-in-class therapy for the treatment of advanced and refractory prostate cancer	The University of Queensland	\$986,510.10

App ID	Chief Investigator Names	Application Title	Administering Institution	Budget
2049917	CIA - Prof David Anderson CIB - Dr Emily Eriksson CIC - Mr Huy Van CID - Dr Ricardo Ataide CIE - Prof Ivo Mueller	Novel biomarkers for improved diagnosis and management of iron deficiency	The Walter and Eliza Hall Institute of Medical Research	\$1,460,069.90
2049929	CIA - Prof Stuart Brierley CIB - Assoc Prof Markus Muttenthaler	A first-in-class oral peptide therapy for chronic visceral pain (CVP) in irritable bowel syndrome (IBS)	South Australian Health and Medical Research Institute Limited	\$999,519.20
2049951	CIA - Prof Daniel Christ CIB - Dr Greg Winter	Development of monoclonal antibody therapy for AL amyloidosis	University of New South Wales	\$1,221,434.40
2049978	CIA - Assoc Prof David Muller CIB - Dr Seth Cheetham CIC - Prof Fiona Simpson CID - Dr Christopher McMillan CIE - Dr Jovin Choo CIF - Assoc Prof Timothy Mercer CIG - Dr Laura Leighton	Needle-free mRNA vaccines for the protection from and treatment of HER2+ breast cancer	The University of Queensland	\$1,139,734.30
2049999	CIA - Prof Alastair Steward CIB - Prof Spencer Williams	Optimising delivery of inhaled agents for chronic respiratory diseases	University of Melbourne	\$768,054.80
2050013	CIA - Prof Stephen O'Leary CIB - Prof Tayla Razmovski CIC - Dr Christofer Bester CID - Dr Wolfram Dueck CIE - Ms Ya Lang Enke	DaWinCI - Cochlear drug delivery for flexible treatment of inner ear disease	University of Melbourne	\$1,238,020.50

App ID	Chief Investigator Names	Application Title	Administering Institution	Budget
2050015	CIA – Prof Stephen O’Leary CIB – Dr Christofer Bester CIC – Prof Tayla Razmovski CID – Prof Robert Briggs CIE – Mr Joerg Pesch CIF – Prof James Bailey CIG – Prof Richard Dowell CIH – Dr Zachary Smith	Hear Alert: Ensuring high value clinical review after cochlear implantation	University of Melbourne	\$1,386,622.50
2050088	CIA – Prof Hang Ta CIB – Prof Huyen Tran CIC – Dr Michael Simmonds CID – Emer Prof Geoff Tansley	Developing novel polymer-based haemostatic sealants for trauma and surgical bleeding	Griffith University	\$899,362.00
2050103	CIA – Prof Stephanie Watson CIB – Dr Yogambha Ramaswamy CIC – Dr Kenneth Ooi CID – Dr Gurvinder Singh CIE – Dr Mahbub Hassan	Developing topical Atorvastatin nanoemulsion to provide relief for sore eyes	University of Sydney	\$630,713.35
2050110	CIA – Prof James Fallon CIB – Prof Mark Cook CIC – Assoc Prof Sophie Payne CID – Mr Robert Klupacs CIE – Dr Dean Karantonis CIF – Dr Alan Lai CIG – Mr Dave Mugan	Abdominal vagus nerve stimulation – side-effect free seizure reduction	The Bionics Institute of Australia	\$1,058,238.40
2050119	CIA – Prof Peter Scammells CIB – Assoc Prof Sheena McGowan CIC – Prof Tania de Koning-Ward	The development of M1 and M17 aminopeptidase inhibitors as antimalarial agents	Monash University	\$880,441.17



App ID	Chief Investigator Names	Application Title	Administering Institution	Budget
2050160	CIA – Prof Marcus Chen CIB – Dr George Taiaroa CIC – Assoc Prof Jonathan Richards CID – Assoc Prof Bridget Freyne CIE – Dr Ella Meumann CIF – Ms Mona Lisa Taouk CIG – Prof Jason Ong CIH – Prof Eric Chow CII – Dr Janet Towns	Development of a point-of-care molecular test for genital ulcer disease (GUD) to enable data driven clinical management	Monash University	\$1,297,890.80
2050183	CIA – Assoc Prof Fiona Brownfoot CIB – Prof Marimuthu Palaniswami CIC – Dr Abu Ul Hassan Sarwar Rana	Novel nanosensor for real-time fetal monitoring in labour: Towards safer births worldwide	University of Melbourne	\$1,330,665.30
			Total	\$16,510,754.72